Literature DB >> 18042659

The demise of anti IL-5 for asthma, or not.

Paul M O'Byrne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18042659     DOI： 10.1164/rccm.200708-1264ED

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  16 in total

Review 1.  Janus kinase-3 dependent inflammatory responses in allergic asthma.

Authors:  Rama Malaviya; Debra L Laskin; Ravi Malaviya
Journal:  Int Immunopharmacol       Date:  2010-04-27       Impact factor: 4.932

2.  CX3CR1 is required for airway inflammation by promoting T helper cell survival and maintenance in inflamed lung.

Authors:  Cyrille Mionnet; Vanessa Buatois; Akira Kanda; Valerie Milcent; Sebastien Fleury; David Lair; Marie Langelot; Yannick Lacoeuille; Edith Hessel; Robert Coffman; Antoine Magnan; David Dombrowicz; Nicolas Glaichenhaus; Valerie Julia
Journal:  Nat Med       Date:  2010-10-31       Impact factor: 53.440

Review 3.  Narrative review: the role of Th2 immune pathway modulation in the treatment of severe asthma and its phenotypes.

Authors:  Stewart J Levine; Sally E Wenzel
Journal:  Ann Intern Med       Date:  2010-02-16       Impact factor: 25.391

4.  IL-35 production by inducible costimulator (ICOS)-positive regulatory T cells reverses established IL-17-dependent allergic airways disease.

Authors:  Gregory S Whitehead; Rhonda H Wilson; Keiko Nakano; Lauranell H Burch; Hideki Nakano; Donald N Cook
Journal:  J Allergy Clin Immunol       Date:  2011-09-08       Impact factor: 10.793

Review 5.  Functions of T cells in asthma: more than just T(H)2 cells.

Authors:  Clare M Lloyd; Edith M Hessel
Journal:  Nat Rev Immunol       Date:  2010-11-09       Impact factor: 53.106

Review 6.  Asthma therapies revisited: what have we learned?

Authors:  Robert F Lemanske
Journal:  Proc Am Thorac Soc       Date:  2009-05-01

7.  Mepolizumab and exacerbations of refractory eosinophilic asthma.

Authors:  Pranabashis Haldar; Christopher E Brightling; Beverley Hargadon; Sumit Gupta; William Monteiro; Ana Sousa; Richard P Marshall; Peter Bradding; Ruth H Green; Andrew J Wardlaw; Ian D Pavord
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

Review 8.  Pulmonary fibrosis: pathogenesis, etiology and regulation.

Authors:  M S Wilson; T A Wynn
Journal:  Mucosal Immunol       Date:  2009-01-07       Impact factor: 7.313

Review 9.  Pathogenesis of aspirin-exacerbated respiratory disease and reactions.

Authors:  Tanya M Laidlaw; Joshua A Boyce
Journal:  Immunol Allergy Clin North Am       Date:  2012-12-23       Impact factor: 3.479

10.  Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma.

Authors:  Garry M Walsh
Journal:  Biologics       Date:  2013-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.